DOCSLIB.ORG

Sedative Antidepressants and Insomnia Antidepressivos Sedativos E Insônia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sedative Antidepressants and Insomnia Antidepressivos Sedativos E Insônia updating Sedative antidepressants and insomnia Antidepressivos sedativos e insônia Walter André dos Santos Moraes,1 Patrick Rademaker Burke,1 Pablo Lorenzon Coutinho,1 Christian Guilleminault,2 Aline Gomes Bittencourt,1 Sergio Tufik,1 Dalva Poyares1 1 Psychobiology Department, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil 2 Human Sleep Research Center, Department of Psychiatry and Behavioral Science, School of Medicine, Stanford University, Palo Alto, CA, USA Abstract Resumo Objective: The present review addresses the relationship between sleep Objetivo: Esta atualização aborda a relação entre sono e depressão e como and depression and how serotonergic transmission is implicated in both a transmissão serotoninérgica está envolvida em ambas condições. Método: conditions. Method: Literature searches were performed in the PubMed Foi realizada uma busca na literatura no PubMed e MedLine até março and MedLine databases up to March 2010. The terms searched were de 2010 com os termos “insônia”, “depressão”, “antidepressivos sedativos” e “insomnia”, “depression”, “sedative antidepressants” and “serotonin”. In “serotonina”. A fim de contemplar os antidepressivos sedativos mais utilizados order to pinpoint the sedative antidepressants most used to treat insomnia, no tratamento da insônia, 34 artigos ISI, principalmente revisões e estudos 34 ISI articles, mainly reviews and placebo-controlled clinical trials, were clínicos placebo-controlados, foram selecionados entre 317 artigos encontrados selected from 317 articles found in our primary search. Results: Sleep na busca inicial. Resultados: Alterações de sono podem aparecer meses antes problems may appear months before the diagnosis of clinical depression do diagnóstico clínico de depressão e persistir após a resolução da depressão. and persist after the resolution of depression. Treatment of insomnia O tratamento dos sintomas de insônia pode melhorar essa doença associada. symptoms may improve this comorbid disease. Some antidepressant Alguns antidepressivos também podem levar à insônia ou sonolência diurna. A drugs can also result in insomnia or daytime sleepiness. Serotonin (5-HT) serotonina (5-HT) demonstra um padrão complexo no que diz respeito ao sono demonstrates a complex pattern with respect to sleep and wakefulness e vigília, o que está relacionado com a variedade de subtipos do receptor 5-HT that is related to the array of 5-HT receptor subtypes involved in different envolvidos em diferentes funções fisiológicas. Acredita-se, atualmente, que a physiological functions. It is now believed that 5HT receptor stimulation 2 estimulação do receptor 5-HT2 esteja envolvida nas alterações da organização is subjacent to insomnia and changes in sleep organization related to do sono e insônia relacionada a alguns antidepressivos. Conclusão: Alguns the use of some antidepressants. Conclusion: Some drugs commonly medicamentos normalmente prescritos para o tratamento de depressão prescribed for the treatment of depression may worsen insomnia and podem piorar a insônia e dificultar a completa recuperação da depressão. Os impair full recovery from depression. 5-HT receptor antagonists are 2 antagonistas do receptor 5-HT2 são drogas promissoras para o tratamento, promising drugs for treatment strategies since they can improve comorbid pois podem melhorar a insônia e depressão associadas. insomnia and depression. Descritores: Neuroquímica; Antidepressivos; Sono; Transtorno depressivo; Descriptors: Neurochemistry; Antidepressive agents; Sleep; Depressive Psicofarmacologia disorder; Psychopharmacology Introduction refers to the quantitative need for sleep that builds up while a Sleep disorders have been reported as symptoms seen in many person is awake and declines during sleep, and is dependent on depressed patients.1 Insomnia may occur in 60-80% of patients how long a person is awake and on how active they are while with major depressive disorder and hypersomnia in approximately awake. The deficiency theory states that Process S in depressive 15-20%.2 Depressive symptoms are important risk factors for patients is deficient in the waking state, which is reflected in insomnia, and depression is considered an important comorbid reduced delta activity. Some authors have described how the delta condition in patients with chronic insomnia of any etiology.3 ratio (delta sleep duration from the first to the second rapid eye Insomnia and sleepiness may also occur as side effects of some movement – REM – period) is reduced in depressive patients.5-7 antidepressant drugs.4 Another model is based on experimental evidence on the reciprocal Different models have been proposed to explain changes in interaction between cholinergic REM-on and aminergic REM- sleep patterns associated with depression. Process S, for instance, off neurons.5,6 REM-suppressive antidepressant therapy supports Correspondence Patrick Rademaker Burke Psychobiology Department, Universidade Federal de São Paulo R. Napoleão de Barros, 925 04024-002 São Paulo, SP, Brasil Submitted: June 29, 2010 Phone: (+55 11) 2149-0155 Accepted: October 11, 2010 Email: [email protected] Revista Brasileira de Psiquiatria 2011 • vol 33 • nº 1 • mar2011 • 91 Moraes WAS et al. this model. Cholinergic/aminergic interaction is subject to both type had higher Beck Depression Inventory scores,10 indicating ultradian and circadian cycles. The internal coincidence model that patients with persistent insomnia were 1.8-3.5 times more supposes that there is a strong circadian oscillator controlling REM likely to remain depressed, compared with patients with no sleep and a weak oscillator controlling the wake–sleep cycle.5 In insomnia.10 This suggests that in addition to being a risk factor depressive patients the strong oscillator is in the advanced phase, for depressive episodes, persistent insomnia perpetuates the illness causing them to sleep late in relation to the biological clock.5 in some elderly patients.11 Consequently, managing insomnia may The activation model5 suggests that depressive patients present enhance the treatment outcome of this comorbid disease.8 There is altered regulation of cortical activation, so that they tend to a dearth of clinical trials examining the effectiveness of hypnotics remain in a hyper-activated state during wakefulness. If, on one in the treatment of depression associated with insomnia. Some hand, brain imaging of glucose metabolism supports the hyper- studies show that relief of sleep disturbance is often determinant activation theory, on the other hand, clinical evidence shows that of compliance with antidepressant treatment. hypo-activation symptoms are frequent and that unidimensional To date there have been few studies evaluating the efficacy of models are inadequate.5 antidepressant drugs in primary insomnia.1 A randomized trial compared the efficacy of trazodone therapy to zolpidem therapy Method and placebo for patients with primary insomnia.12 Compared This is an updated report which focuses on the relationship to zolpidem, trazodone was less effective in improving sleep between sleep, insomnia, 5HT and depression, with particular disturbances in those patients.12 Despite the widespread use of attention to sedative antidepressants in the context of insomnia. trazodone for insomnia, there are limited data available, most of Other effects of antidepressants, with the exception of sedation, them on insomnia associated with depression.12 More studies are are beyond the scope of this report. For concision, we included needed on the effect and long-term safety of trazodone in primary the most commonly prescribed compounds of this class, which insomnia and in the elderly, among whom its use is frequent. A included: trazodone, mirtazapine, agomelatine and doxepine randomized crossover study, using polysomnography and patient Literature searches were performed in the PubMed and MedLine reporting, evaluated doxepin therapy for adults with primary databases up to March 2010. The terms searched were “insomnia”, insomnia,1,13 and has shown its efficacy in improving sleep.13 “depression”, “sedative antidepressants“ and “serotonin“. We Trimipramine and paroxetine were also analyzed, but results were started with 317 references and have given priority to reviews not promising.1 Thus, there is no evidence that antidepressants (15), randomized placebo-controlled studies and other controlled are superior to the new nonbenzodiazepine hypnotics to treat studies (11), but also included update articles (2), cohort primary insomnia. and epidemiological studies (4), an open label study (1) and experimental data in humans and animals (3). Case reports and Selective serotonin reuptake inhibitors and their articles assessing other sedative-hypnotic substances were excluded. impact on sleep A total of 34 references were included. The most common sleep disturbances in depressed patients, as Among reviews and controlled studies we have included about documented in visually-scored polysomnograms, include: three articles for each of the mentioned sedative antidepressants. 1) Altered duration and sustenance of sleep. Total sleep time is reduced, due to an increase in sleep latency and wake time after The relationship between sleep and depression sleep onset (WASO), and early morning awakening. However, Depressive symptoms are the greatest and most consistent risk 15-20% present hypersomnia.5,14 Depressive individuals frequently factors for insomnia, which is often the presenting symptom in show sleep-stage changes and
Load more

Recommended publications
  • By ANDREA PETERSEN Getty Images for Those Who Have Trouble
    By ANDREA PETERSEN Getty Images For those who have trouble sleeping, there may soon be new ways to summon the sandman. Several pharmaceutical companies are working on new approaches to treat insomnia. The compounds are meant to work differently than current leading sleep aids such as Ambien and Lunesta, which, while generally safe, can have troubling side effects because they act on many areas of the brain. By contrast, many of the drugs being developed target particular systems responsible for sleep and wakefulness. The hope is that they will have fewer side effects and less potential for addiction and cognition problems the next day. New drugs are in the works to treat insomnia, which affects 10% to 30% of Americans (and more women than men). Andrea Peterson explains. About 30% of American adults have insomnia symptoms each year, scientific studies estimate. Some 10% of the population has chronic insomnia, which is generally defined as having difficulty sleeping at least three times a week for a month or more. Chronic insomnia sufferers also feel tired, cranky or foggy-headed during the day. Insomnia comes in various forms. Some people have a tough time falling asleep and others wake in the middle of the night and have trouble getting back to sleep. Some people rise for the day too early. Insomnia can increase the risk for other conditions, including heart disease, diabetes and depression. Merck & Co. is investigating a compound that inhibits the action of orexin receptors, which in turn interferes with the activity of orexin, a chemical in the brain that produces alertness.
    [Show full text]
  • R Graphics Output
    Dexamethasone sodium phosphate ( 0.339 ) Melengestrol acetate ( 0.282 ) 17beta−Trenbolone ( 0.252 ) 17alpha−Estradiol ( 0.24 ) 17alpha−Hydroxyprogesterone ( 0.238 ) Triamcinolone ( 0.233 ) Zearalenone ( 0.216 ) CP−634384 ( 0.21 ) 17alpha−Ethinylestradiol ( 0.203 ) Raloxifene hydrochloride ( 0.203 ) Volinanserin ( 0.2 ) Tiratricol ( 0.197 ) trans−Retinoic acid ( 0.192 ) Chlorpromazine hydrochloride ( 0.191 ) PharmaGSID_47315 ( 0.185 ) Apigenin ( 0.183 ) Diethylstilbestrol ( 0.178 ) 4−Dodecylphenol ( 0.161 ) 2,2',6,6'−Tetrachlorobisphenol A ( 0.156 ) o,p'−DDD ( 0.155 ) Progesterone ( 0.152 ) 4−Hydroxytamoxifen ( 0.151 ) SSR150106 ( 0.149 ) Equilin ( 0.3 ) 3,5,3'−Triiodothyronine ( 0.256 ) 17−Methyltestosterone ( 0.242 ) 17beta−Estradiol ( 0.24 ) 5alpha−Dihydrotestosterone ( 0.235 ) Mifepristone ( 0.218 ) Norethindrone ( 0.214 ) Spironolactone ( 0.204 ) Farglitazar ( 0.203 ) Testosterone propionate ( 0.202 ) meso−Hexestrol ( 0.199 ) Mestranol ( 0.196 ) Estriol ( 0.191 ) 2,2',4,4'−Tetrahydroxybenzophenone ( 0.185 ) 3,3,5,5−Tetraiodothyroacetic acid ( 0.183 ) Norgestrel ( 0.181 ) Cyproterone acetate ( 0.164 ) GSK232420A ( 0.161 ) N−Dodecanoyl−N−methylglycine ( 0.155 ) Pentachloroanisole ( 0.154 ) HPTE ( 0.151 ) Biochanin A ( 0.15 ) Dehydroepiandrosterone ( 0.149 ) PharmaCode_333941 ( 0.148 ) Prednisone ( 0.146 ) Nordihydroguaiaretic acid ( 0.145 ) p,p'−DDD ( 0.144 ) Diphenhydramine hydrochloride ( 0.142 ) Forskolin ( 0.141 ) Perfluorooctanoic acid ( 0.14 ) Oleyl sarcosine ( 0.139 ) Cyclohexylphenylketone ( 0.138 ) Pirinixic acid ( 0.137 )
    [Show full text]
  • 204569Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204569Orig1s000 MEDICAL REVIEW(S) Cross Discipline Team Leader Review 3. CMC/Device Dr. Khairuzzaman found the drug product portion of the NDA to be acceptable, and without need for phase 4 commitments. Dr. Sapru’s review stated that with the exception of a pending issue concerning the control of potential genotoxic impurity (b) (4) the NDA was approvable in terms of drug substance. Dr. Suarez found that the NDA was acceptable from a biopharmaceutics perspective. The Office of Compliance issuance of an acceptable recommendation for drug substance manufacturing and testing facilities was pending at the time of this review. 4. Nonclinical Pharmacology/Toxicology Dr. Richard Siarey completed the primary nonclinical review, and Dr. Lois Freed completed a supervisory memo. Dr. Siarey’s overall conclusion was that from a nonclinical perspective, approval of the suvorexant NDA was recommended. However, he found evidence that catapelxy was observed in dogs exposed to MK-4305 (suvorexant) near Tmax, although he concluded that additional information could have been gained by studying the drug in an experimental model that has been used for diagnosing cataplexy in dogs. Dr. Siarey suggested that since cataplexy occurred in dogs near Tmax, a time at which if used for insomnia patients would ordinarily be in bed, safety concern for humans was reduced. Dr. Siarey also found that the neurobehavioral assessment in the pre- and post-natal developmental study was not complete, as the passive avoidance tests was performed too early in development, while learning/acquisition tests and retention/memory tests were not conducted.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates Et Al
    US008598119B2 (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates et al. (45) Date of Patent: Dec. 3, 2013 (54) METHODS AND COMPOSITIONS FOR AOIN 43/00 (2006.01) SLEEP DSORDERS AND OTHER AOIN 43/46 (2006.01) DSORDERS AOIN 43/62 (2006.01) AOIN 43/58 (2006.01) (75) Inventors: Sharon Mates, New York, NY (US); AOIN 43/60 (2006.01) Allen Fienberg, New York, NY (US); (52) U.S. Cl. Lawrence Wennogle, New York, NY USPC .......... 514/114: 514/171; 514/217: 514/220; (US) 514/229.5: 514/250 (58) Field of Classification Search (73) Assignee: Intra-Cellular Therapies, Inc. NY (US) None See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 215 days. U.S. PATENT DOCUMENTS (21) Appl. No.: 12/994,560 6,552,017 B1 4/2003 Robichaud et al. 2007/0203120 A1 8, 2007 McDevitt et al. (22) PCT Filed: May 27, 2009 FOREIGN PATENT DOCUMENTS (86). PCT No.: PCT/US2O09/OO3261 S371 (c)(1), WO WOOOf77OO2 * 6, 2000 (2), (4) Date: Nov. 24, 2010 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2009/145900 Rye (Sleep Disorders and Parkinson's Disease, 2000, accessed online http://www.waparkinsons.org/edu research/articles/Sleep PCT Pub. Date: Dec. 3, 2009 Disorders.html), 2 pages.* Alvir et al. Clozapine-Induced Agranulocytosis. The New England (65) Prior Publication Data Journal of Medicine, 1993, vol. 329, No. 3, pp. 162-167.* US 2011/0071080 A1 Mar.
    [Show full text]
  • Novel Cyclodextrin Derivatives Presented at the 3Rd European Conference on Cyclodextrins
    VOLUME 27. No. 11. NOVEMBER 2013 ISSN 0951-256X October 2-4, 2013, Antalya, Turkey Novel cyclodextrin derivatives presented at the 3rd European Conference on Cyclodextrins This year’s European Conference on Cyclodextrins organized by Prof. Erem Bilensoy, Hacettepe University, Ankara brought 50 oral presentations and 65 posters. Most of the presented works covered the main theme of the congress: ”multifunctional excipient potential of cyclodextrins in pharmaceutical, cosmetic and biomedical industries”. The large number of the presented works dealing with novel cyclodextrin derivatives clearly shows that recently there has been a renewed interest in functionalization of cyclodextrins in order to extend the utilization of these derivatives as tools in catalysis, drug delivery, formulation and stabilization of active molecules and cosmetic ingredients. This short paper gives a brief review of the presented novel cyclodextrin derivatives, summarizes their synthetic methodologies and the field of their applications. Extended abstracts will be published in the Journal of Inclusion Phenomena and Macrocyclic Chemistry after peer review. The references given here are the papers of the cited authors on similar topics presented at the conference. NOVEL CYCLODEXTRIN POLYMERS AND NANOSPONGES Phosphorus-containing cyclodextrin polymers presented by Prof. Catherine Amiel A very attractive new cyclodextrin (CD) based polymeric system presented by Prof. Amiel combines the advantages of cyclodextrin polymers (formation of inclusion complexes with apolar guests) and phosphorus-containing polymers (biocompatibility, calcium affinity). These VOLUME 27. No 11. polymeric systems are promising candidates to be used in biomedical applications that jointly require calcium delivery and transport of lipophilic bioactive molecules. A non-toxic cyclic sodium trimetaphosphate (STMP) was used as a cross-linking agent under basic conditions.
    [Show full text]
  • Journal of Psychopharmacology
    Journal of Psychopharmacology http://jop.sagepub.com/ British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders SJ Wilson, DJ Nutt, C Alford, SV Argyropoulos, DS Baldwin, AN Bateson, TC Britton, C Crowe, D-J Dijk, CA Espie, P Gringras, G Hajak, C Idzikowski, AD Krystal, JR Nash, H Selsick, AL Sharpley and AG Wade J Psychopharmacol 2010 24: 1577 originally published online 2 September 2010 DOI: 10.1177/0269881110379307 The online version of this article can be found at: http://jop.sagepub.com/content/24/11/1577 Published by: http://www.sagepublications.com On behalf of: British Association for Psychopharmacology Additional services and information for Journal of Psychopharmacology can be found at: Email Alerts: http://jop.sagepub.com/cgi/alerts Subscriptions: http://jop.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav Citations: http://jop.sagepub.com/content/24/11/1577.refs.html Downloaded from jop.sagepub.com at University of Otago Library on March 11, 2011 Original Paper British Association for Psychopharmacology consensus statement on evidence-based Journal of Psychopharmacology treatment of insomnia, parasomnias and 24(11) 1577–1600 ! The Author(s) 2010 circadian rhythm disorders Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881110379307 jop.sagepub.com SJ Wilson1, DJ Nutt2, C Alford3, SV Argyropoulos4, DS Baldwin5, AN Bateson6, TC Britton7, C Crowe8, D-J Dijk9, CA Espie10, P Gringras11, G Hajak12, C Idzikowski13, AD Krystal14, JR Nash15, H Selsick16, AL Sharpley17 and AG Wade18 Abstract Sleep disorders are common in the general population and even more so in clinical practice, yet are relatively poorly understood by doctors and other health care practitioners.
    [Show full text]
  • Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT
    Datasheet Inhibitors / Agonists / Screening Libraries A DRUG SCREENING EXPERT Product Name : Volinanserin Catalog Number : T5389 CAS Number : 139290-65-6 Molecular Formula : C22H28FNO3 Molecular Weight : 373.46 Description: Volinanserin (MDL 100907) is a potent and selective antagonist of the serotonin receptor 5-HT2 (Ki: 0.36 nM) and shows 300-fold selectivity for 5-HT2 receptor over 5-HT1c, alpha-1 adrenergic and sigma receptors. Storage: 2 years -80°C in solvent; 3 years -20°C powder; DMSO 100 mg/mL (267.8 mM) Solubility Ethanol 18 mg/mL (48.2 mM) ( < 1 mg/ml refers to the product slightly soluble or insoluble ) Receptor (IC50) 5-HT2 receptor 0.36 nM (Ki) In vitro Activity MDL 100,907 demonstrated low nanomolar or subnanomolar binding in vitro at the 5-HT2A receptor and showed a > 100-fold separation from all other receptors measured. MDL 100,907 had subnanomolar potency as a 5-HT2A antagonist in vitro in reversing 5-HT-stimulated inositol phosphate accumulation in NIH 3T3 cells transfected with the rat 5-HT2A receptor [2]. In vivo Activity In mice, MDL 100,907 blocked amphetamine-stimulated locomotion at doses that did not significantly affect apomorphine- stimulated climbing behavior. When administered chronically, MDL 100,907 selectively reduced the number of spontaneously active A10 neurons [1]. In vivo, MDL 100,907 potently inhibited 5-methoxy-N, N-dimethyltryptamine-induced head twitches in mice or 5-hydroxytryptophan-induced head twitches in rats. In vivo, functional tests in mice revealed a > 500-fold separation between doses that produced 5-HT2A antagonism and doses that produced alpha 1-adrenergic or striatal D2 antagonism [2].
    [Show full text]
  • A Phase 3, Multicenter, Randomized, Double-Blind
    Official Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment NCT Number: NCT03999918 Document Date: 21 Jun 2020 CLINICAL STUDY PROTOCOL UNMASKED PROTOCOL A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment Protocol Number: ACP-103-054 Amendment 4 EudraCT Number: 2018-003251-37 Original Protocol Date: 30 August 2018 Protocol Amendment 1 Date: 05 December 2018 Protocol Amendment 2 Date: 18 March 2019 Protocol Amendment 3 Date: 29 October 2019 Protocol Amendment 4 Date: 21 June 2020 Confidentiality Statement This protocol is the confidential information of ACADIA Pharmaceuticals Inc. and is intended solely for the guidance of the clinical investigation. This protocol may not be disclosed to parties not associated with the clinical investigation or used for any purpose without the prior written consent of ACADIA Pharmaceuticals Inc. Confidential and Proprietary Information of ACADIA Pharmaceuticals Inc. Page 1 of 81 Study: ACP-103-054 Final Version: 1.0 Clinical Study Protocol Amendment 4 UNMASKED VERSION Date: 21 June 2020 SPONSOR SIGNATURE PAGE Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment ACADIA President: President ACADIA Pharmaceuticals Inc. See appended electronic signature page Signature Date ACADIA Study Lead: Executive Director, Clinical Research ACADIA Pharmaceuticals Inc.
    [Show full text]
  • Emerging Anti-Insomnia Drugs: Tackling Sleeplessness and the Quality of Wake Time
    REVIEWS Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time Keith A. Wafford* and Bjarke Ebert‡ Abstract | Sleep is essential for our physical and mental well being. However, when novel hypnotic drugs are developed, the focus tends to be on the marginal and statistically significant increase in minutes slept during the night instead of the effects on the quality of wakefulness. Recent research on the mechanisms underlying sleep and the control of the sleep–wake cycle has the potential to aid the development of novel hypnotic drugs; however, this potential has not yet been realized. Here, we review the current understanding of how hypnotic drugs act, and discuss how new, more effective drugs and treatment strategies for insomnia might be achieved by taking into consideration the daytime consequences of disrupted sleep. Primary insomnia Humans spend approximately one-third of their lifetime Insomnia is defined as difficulty in initiating and/or Patients who suffer from sleeping, but we still know relatively little about why this maintaining sleep. The incidence of insomnia in the gen- sleeplessness for at least process is so critical for every living animal. Current eral population is between 10–30%, and approximately 1 month that cannot be thinking suggests that waking activity is relatively 50% of the cases complain of serious daytime conse- attributed to a medical, dynamic in terms of using the body’s resources: breaking quences, such as inability to concentrate, reduced energy psychiatric or an environmental cause (such as drug abuse or down proteins, gathering information and expending and memory problems. When this persists for more medications).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0072964 A1 Mates Et Al
    US 20150.072964A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0072964 A1 Mates et al. (43) Pub. Date: Mar. 12, 2015 (54) NOVELMETHODS filed on Apr. 14, 2012, provisional application No. 61/624.293, filed on Apr. 14, 2012, provisional appli (71) Applicant: INTRA-CELLULAR THERAPIES, cation No. 61/671,713, filed on Jul. 14, 2012, provi INC., New York, NY (US) sional application No. 61/671,723, filed on Jul. 14, 2012. (72) Inventors: Sharon Mates, New York, NY (US); Robert Davis, New York, NY (US); Publication Classification Kimberly Vanover, New York, NY (US); Lawrence Wennogle, New York, (51) Int. Cl. NY (US) C07D 47L/6 (2006.01) A613 L/4985 (2006.01) (21) Appl. No.: 14/394,469 A6II 45/06 (2006.01) (52) U.S. Cl. (22) PCT Fled: Apr. 14, 2013 CPC .............. C07D 471/16 (2013.01); A61K 45/06 (2013.01); A61 K3I/4985 (2013.01) (86) PCT NO.: PCT/US13A36512 USPC ...... 514/171; 514/250; 514/211.13: 514/217; S371 (c)(1), 514/214.02: 514/220 (2) Date: Oct. 14, 2014 (57) ABSTRACT Use of particular substituted heterocycle fused gamma-car Related U.S. Application Data boline compounds as pharmaceuticals for the treatment of (60) Provisional application No. 61/624.291, filed on Apr. agitation, aggressive behaviors, posttraumatic stress disorder 14, 2012, provisional application No. 61/624,292, or impulse control disorders. US 2015/0072964 A1 Mar. 12, 2015 NOVEL METHODS One type of ICD is Intermittent Explosive Disorder (IED) which involves violence or rage. There is a loss of control CROSS REFERENCE TO RELATED grossly out of proportion to any precipitating psychosocial APPLICATIONS stresses.
    [Show full text]
  • WO 2010/065547 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 10 June 2010 (10.06.2010) WO 2010/065547 Al (51) International Patent Classification: (74) Agents: AMII, Lisa, A. et al.; Morrison & Foerster LLP, A61M 15/00 (2006.01) A61M 9/00 (2006.01) 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). A61M 16/00 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US2009/066272 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (22) International Filing Date: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 1 December 2009 (01 .12.2009) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (25) Filing Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (26) Publication Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (30) Priority Data: SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, 61/1 19,015 1 December 2008 (01 .12.2008) US TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US): MAP (84) Designated States (unless otherwise indicated, for every PHARMACEUTICALS, INC. [US/US]; 2400 Bayshore kind of regional protection available): ARIPO (BW, GH, Parkway, Suite 200, Mountain View, CA 94043 (US).
    [Show full text]
  • Copyright by Holly L. Chapman 2020
    Copyright by Holly L. Chapman 2020 EFFECTS OF VOLINANSERIN ON SLEEP AND WAKE STAGES AND THE EEG SPECTRUM DURING NICOTINE WITHDRAWAL IN RATS by Holly L. Chapman, B.S. THESIS Presented to the Faculty of The University of Houston-Clear Lake In Partial Fulfillment Of the Requirements For the Degree MASTER OF SCIENCE in Psychology THE UNIVERSITY OF HOUSTON-CLEAR LAKE MAY, 2020 EFFECTS OF VOLINANSERIN ON SLEEP AND WAKE STAGES AND THE EEG SPECTRUM DURING NICOTINE WITHDRAWAL IN RATS by Holly L. Chapman APPROVED BY __________________________________________ Christopher P. Ward, Ph.D., Chair __________________________________________ David H. Malin, Ph.D., Co-Chair RECEIVED/APPROVED BY THE COLLEGE OF HUMAN SCIENCES AND HUMANITIES: Samuel Gladden, Ph.D., Associate Dean __________________________________________ Rick Short, Ph.D., Dean Dedication To my family, whose unflinching support means the world to me and I hope one day I can return in kind. Acknowledgements To everyone else that believed, persisted, and achieved around me and gave me the strength to do the same. Special acknowledgements go out to my thesis committee Dr. Ward and Dr. Malin for having the patience to get this project off the ground, again, and make the most of our resources. Huge thanks to Joseph R. Campbell and Ping Sun Tsai for fast-tracking my motivation/sanity and digging into the science and reviewing my writing with me. v ABSTRACT EFFECTS OF VOLINANSERIN ON SLEEP AND WAKE STAGES AND THE EEG SPECTRUM DURING NICOTINE WITHDRAWAL IN RATS Holly L. Chapman University of Houston-Clear Lake, 2020 Thesis Chair: Dr. Christopher P. Ward Co-Chair: Dr.
    [Show full text]